- Trial phase
- Approved and marketed
- Time to market
- Already approved and commercialized. No additional regulatory steps are needed for the current indication.
- Why 4/10
- HEPAGAM is an already-approved, marketed product with no pending regulatory decision or pivotal readout. It is one of six FDA-approved products in Kamada's diversified portfolio, not the sole value driver. The next hard catalyst for the stock would be the full-year 2026 earnings report (early 2027), which is a quarterly earnings event, not a drug-specific binary. Per the rubric, an approved drug with no pending regulatory decision scores 3-5; a 4 reflects that HEPAGAM contributes to a growing commercial portfolio but is not a standalone binary catalyst.
HEPAGAM is a steady commercial product within a diversified portfolio, not a binary catalyst. Kamada's next major event is the Q4/full-year 2026 earnings report in early 2027, where investors will watch for continued demand trends across the product portfolio including HEPAGAM. The stock trades at $8.13 with a mean analyst target of $13.50, but the recent insider selling and institutional trimming warrant monitoring.
Price Chart
Executive Summary
HEPAGAM (HEPAGAM B) is an FDA-approved hepatitis B immune globulin product marketed by Kamada Ltd. (NASDAQ: KMDA), an Israeli biopharmaceutical company focused on plasma-derived therapies. The drug provides passive immunity against hepatitis B for post-exposure prophylaxis. It is one of six FDA-approved plasma-derived products in Kamada's commercial portfolio and contributed to the company's record financial results in the first nine months of 2026. As an already-approved, marketed drug with no pending regulatory catalysts, HEPAGAM is a steady commercial contributor rather than a binary event driver for the stock.
How It Works
HEPAGAM is a plasma-derived antibody therapy (immune globulin) that provides immediate, passive immunity against the hepatitis B virus. It is extracted from the blood plasma of donors who have high levels of hepatitis B antibodies, and when injected into a patient, it neutralizes the virus and prevents infection after exposure.
Trial Status
HEPAGAM B is an FDA-approved, commercially marketed product. It is one of six FDA-approved plasma-derived biopharmaceutical products in Kamada's commercial portfolio, alongside KEDRAB (rabies immune globulin), VARIZIG (varicella immune globulin), CYTOGAM (cytomegalovirus immune globulin), WINRHO SDF (Rho(D) immune globulin), and GLASSIA (alpha-1 proteinase inhibitor). Kamada reported that stronger demand for KEDRAB, VARIZIG, and HEPAGAM supported its record financial performance in the first nine months of 2026.
The Two-Sided Case
Upcoming Catalysts
- No HEPAGAM-specific binary catalysts are scheduled. The drug is already approved and marketed. Kamada's next company-level catalyst is the Q4 2026 / full-year 2026 earnings report, expected in early 2027.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Kamada Ltd. PRESS-RELEASE KMDA ·Originating report